Maze Therapeutics (MAZE) Competitors $29.26 +0.76 (+2.67%) As of 10/15/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MAZE vs. ACLX, KYMR, PTGX, MENS, CRNX, ZLAB, AKRO, AAPG, MIRM, and ACADShould you be buying Maze Therapeutics stock or one of its competitors? The main competitors of Maze Therapeutics include Arcellx (ACLX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Jyong Biotech (MENS), Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), Ascentage Pharma Group International (AAPG), Mirum Pharmaceuticals (MIRM), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Maze Therapeutics vs. Its Competitors Arcellx Kymera Therapeutics Protagonist Therapeutics Jyong Biotech Crinetics Pharmaceuticals Zai Lab Akero Therapeutics Ascentage Pharma Group International Mirum Pharmaceuticals ACADIA Pharmaceuticals Arcellx (NASDAQ:ACLX) and Maze Therapeutics (NASDAQ:MAZE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings. Do analysts recommend ACLX or MAZE? Arcellx presently has a consensus target price of $112.69, indicating a potential upside of 22.00%. Maze Therapeutics has a consensus target price of $33.83, indicating a potential upside of 15.63%. Given Arcellx's higher probable upside, analysts clearly believe Arcellx is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcellx 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.87Maze Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Does the media prefer ACLX or MAZE? In the previous week, Arcellx had 5 more articles in the media than Maze Therapeutics. MarketBeat recorded 8 mentions for Arcellx and 3 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 0.62 beat Arcellx's score of 0.04 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcellx 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Maze Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in ACLX or MAZE? 96.0% of Arcellx shares are owned by institutional investors. 8.4% of Arcellx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is ACLX or MAZE more profitable? Maze Therapeutics has a net margin of 0.00% compared to Arcellx's net margin of -329.93%. Maze Therapeutics' return on equity of 0.00% beat Arcellx's return on equity.Company Net Margins Return on Equity Return on Assets Arcellx-329.93% -43.04% -27.41% Maze Therapeutics N/A N/A N/A Which has better valuation & earnings, ACLX or MAZE? Maze Therapeutics has higher revenue and earnings than Arcellx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcellx$107.94M47.46-$107.35M-$3.42-27.01Maze Therapeutics$167.50M7.66$52.23MN/AN/A SummaryMaze Therapeutics beats Arcellx on 8 of the 14 factors compared between the two stocks. Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAZE vs. The Competition Export to ExcelMetricMaze TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.25B$3.37B$6.12B$10.45BDividend YieldN/A2.30%5.73%4.78%P/E RatioN/A22.7785.3827.36Price / Sales7.66491.80602.69196.46Price / Cash186.1646.7037.4661.86Price / Book-4.1210.5512.516.81Net Income$52.23M-$52.58M$3.32B$276.80M7 Day Performance1.74%0.09%0.60%0.42%1 Month Performance24.72%15.61%10.53%7.86%1 Year PerformanceN/A15.13%74.30%41.24% Maze Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAZEMaze Therapeutics3.1627 of 5 stars$29.26+2.7%$33.83+15.6%N/A$1.25B$167.50M0.00121ACLXArcellx1.8432 of 5 stars$85.07+3.4%$114.31+34.4%+2.7%$4.56B$107.94M-24.8780Analyst RevisionHigh Trading VolumeKYMRKymera Therapeutics1.3581 of 5 stars$57.90+3.4%$61.26+5.8%+40.4%$4.14B$44.71M-16.69170Insider TradePTGXProtagonist Therapeutics1.7197 of 5 stars$64.83-0.2%$68.36+5.5%+63.1%$4.04B$209.18M92.62120Analyst ForecastInsider TradeGap DownMENSJyong BiotechN/A$48.00-7.7%N/AN/A$3.95BN/A0.0031CRNXCrinetics Pharmaceuticals3.7527 of 5 stars$40.86-1.6%$74.45+82.2%-23.4%$3.85B$1.39M-9.94210ZLABZai Lab2.7826 of 5 stars$33.75-0.3%$56.35+67.0%+18.6%$3.78B$398.99M-16.541,869News CoverageAKROAkero Therapeutics3.6944 of 5 stars$46.10-0.7%$81.14+76.0%+79.1%$3.71BN/A-23.0530Insider TradeAAPGAscentage Pharma Group InternationalN/A$39.38-1.0%N/AN/A$3.71B$134.35M0.00600Gap UpMIRMMirum Pharmaceuticals2.9089 of 5 stars$72.95+1.7%$76.50+4.9%+91.9%$3.66B$429.16M-60.29140Analyst RevisionACADACADIA Pharmaceuticals4.5235 of 5 stars$21.80+2.0%$29.12+33.6%+45.8%$3.61B$1.02B16.39510Analyst Forecast Related Companies and Tools Related Companies Arcellx Competitors Kymera Therapeutics Competitors Protagonist Therapeutics Competitors Jyong Biotech Competitors Crinetics Pharmaceuticals Competitors Zai Lab Competitors Akero Therapeutics Competitors Ascentage Pharma Group International Competitors Mirum Pharmaceuticals Competitors ACADIA Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAZE) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
